Cladribine for Highly Active Relapsing Multiple Sclerosis

Prescriber - United Kingdom
doi 10.1002/psb.1652
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis

Advances in Therapy
MedicinePharmacology
2019English

Pnd62 - Cost-Effectiveness of Cladribine Tablets in the Treatment of Patients With Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Health State Utilities in Patients With Relapsing Remitting Multiple Sclerosis Treated With Cladribine Tablets

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Pnd26 - Cost Implications of a Novel Weight Dosed Treatment for Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Natalizumab Therapy for Highly Active Pediatric Multiple Sclerosis

JAMA Neurology
Neurology
2013English

Pnd65 - Cost-Effectiveness Analysis of Drugs Used for the Treatment of Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd27 - Cost Implications in the Selection of First Line Treatment for Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Emerging Therapies for Relapsing Multiple Sclerosis

Archives of Neurology
2009English

Relapsing-Remitting Multiple Sclerosis and Human Herpesvirus 6 Active Infection

Archives of Neurology
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy